170 related articles for article (PubMed ID: 26844277)
1. Screening for Pancreatic Adenocarcinoma in BRCA2 Mutation Carriers: Results of a Disease Simulation Model.
Pandharipande PV; Jeon A; Heberle CR; Dowling EC; Kong CY; Chung DC; Brugge WR; Hur C
EBioMedicine; 2015 Dec; 2(12):1980-6. PubMed ID: 26844277
[TBL] [Abstract][Full Text] [Related]
2. Genetic testing to guide screening for pancreatic ductal adenocarcinoma: Results of a microsimulation model.
Peters MLB; Eckel A; Lietz A; Seguin C; Mueller P; Hur C; Pandharipande PV
Pancreatology; 2022 Sep; 22(6):760-769. PubMed ID: 35752568
[TBL] [Abstract][Full Text] [Related]
3. Identification of germline genetic mutations in patients with pancreatic cancer.
Salo-Mullen EE; O'Reilly EM; Kelsen DP; Ashraf AM; Lowery MA; Yu KH; Reidy DL; Epstein AS; Lincoln A; Saldia A; Jacobs LM; Rau-Murthy R; Zhang L; Kurtz RC; Saltz L; Offit K; Robson ME; Stadler ZK
Cancer; 2015 Dec; 121(24):4382-8. PubMed ID: 26440929
[TBL] [Abstract][Full Text] [Related]
4. Annual screening strategies in BRCA1 and BRCA2 gene mutation carriers: a comparative effectiveness analysis.
Lowry KP; Lee JM; Kong CY; McMahon PM; Gilmore ME; Cott Chubiz JE; Pisano ED; Gatsonis C; Ryan PD; Ozanne EM; Gazelle GS
Cancer; 2012 Apr; 118(8):2021-30. PubMed ID: 21935911
[TBL] [Abstract][Full Text] [Related]
5. Bilateral prophylactic mastectomy in BRCA mutation carriers: what surgeons need to know.
Franceschini G; Di Leone A; Terribile D; Sanchez MA; Masetti R
Ann Ital Chir; 2019; 90():1-2. PubMed ID: 30872561
[TBL] [Abstract][Full Text] [Related]
6. Differences in natural history between breast cancers in BRCA1 and BRCA2 mutation carriers and effects of MRI screening-MRISC, MARIBS, and Canadian studies combined.
Heijnsdijk EA; Warner E; Gilbert FJ; Tilanus-Linthorst MM; Evans G; Causer PA; Eeles RA; Kaas R; Draisma G; Ramsay EA; Warren RM; Hill KA; Hoogerbrugge N; Wasser MN; Bergers E; Oosterwijk JC; Hooning MJ; Rutgers EJ; Klijn JG; Plewes DB; Leach MO; de Koning HJ
Cancer Epidemiol Biomarkers Prev; 2012 Sep; 21(9):1458-68. PubMed ID: 22744338
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness of alternating magnetic resonance imaging and digital mammography screening in BRCA1 and BRCA2 gene mutation carriers.
Cott Chubiz JE; Lee JM; Gilmore ME; Kong CY; Lowry KP; Halpern EF; McMahon PM; Ryan PD; Gazelle GS
Cancer; 2013 Mar; 119(6):1266-76. PubMed ID: 23184400
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness of screening BRCA1/2 mutation carriers with breast magnetic resonance imaging.
Plevritis SK; Kurian AW; Sigal BM; Daniel BL; Ikeda DM; Stockdale FE; Garber AM
JAMA; 2006 May; 295(20):2374-84. PubMed ID: 16720823
[TBL] [Abstract][Full Text] [Related]
9. A simulation model to predict the impact of prophylactic surgery and screening on the life expectancy of BRCA1 and BRCA2 mutation carriers.
Sigal BM; Munoz DF; Kurian AW; Plevritis SK
Cancer Epidemiol Biomarkers Prev; 2012 Jul; 21(7):1066-77. PubMed ID: 22556274
[TBL] [Abstract][Full Text] [Related]
10. BRCA germline mutations in Jewish patients with pancreatic adenocarcinoma.
Ferrone CR; Levine DA; Tang LH; Allen PJ; Jarnagin W; Brennan MF; Offit K; Robson ME
J Clin Oncol; 2009 Jan; 27(3):433-8. PubMed ID: 19064968
[TBL] [Abstract][Full Text] [Related]
11. The incidence of pancreatic cancer in BRCA1 and BRCA2 mutation carriers.
Iqbal J; Ragone A; Lubinski J; Lynch HT; Moller P; Ghadirian P; Foulkes WD; Armel S; Eisen A; Neuhausen SL; Senter L; Singer CF; Ainsworth P; Kim-Sing C; Tung N; Friedman E; Llacuachaqui M; Ping S; Narod SA;
Br J Cancer; 2012 Dec; 107(12):2005-9. PubMed ID: 23099806
[TBL] [Abstract][Full Text] [Related]
12. Cancer risks in BRCA2 mutation carriers.
Breast Cancer Linkage Consortium
J Natl Cancer Inst; 1999 Aug; 91(15):1310-6. PubMed ID: 10433620
[TBL] [Abstract][Full Text] [Related]
13. Statewide Retrospective Review of Familial Pancreatic Cancer in Delaware, and Frequency of Genetic Mutations in Pancreatic Cancer Kindreds.
Catts ZA; Baig MK; Milewski B; Keywan C; Guarino M; Petrelli N
Ann Surg Oncol; 2016 May; 23(5):1729-35. PubMed ID: 26727920
[TBL] [Abstract][Full Text] [Related]
14. BRCA1 and BRCA2 germline mutations are frequently demonstrated in both high-risk pancreatic cancer screening and pancreatic cancer cohorts.
Lucas AL; Frado LE; Hwang C; Kumar S; Khanna LG; Levinson EJ; Chabot JA; Chung WK; Frucht H
Cancer; 2014 Jul; 120(13):1960-7. PubMed ID: 24737347
[TBL] [Abstract][Full Text] [Related]
15. Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers.
Kuchenbaecker KB; Hopper JL; Barnes DR; Phillips KA; Mooij TM; Roos-Blom MJ; Jervis S; van Leeuwen FE; Milne RL; Andrieu N; Goldgar DE; Terry MB; Rookus MA; Easton DF; Antoniou AC; ; McGuffog L; Evans DG; Barrowdale D; Frost D; Adlard J; Ong KR; Izatt L; Tischkowitz M; Eeles R; Davidson R; Hodgson S; Ellis S; Nogues C; Lasset C; Stoppa-Lyonnet D; Fricker JP; Faivre L; Berthet P; Hooning MJ; van der Kolk LE; Kets CM; Adank MA; John EM; Chung WK; Andrulis IL; Southey M; Daly MB; Buys SS; Osorio A; Engel C; Kast K; Schmutzler RK; Caldes T; Jakubowska A; Simard J; Friedlander ML; McLachlan SA; Machackova E; Foretova L; Tan YY; Singer CF; Olah E; Gerdes AM; Arver B; Olsson H
JAMA; 2017 Jun; 317(23):2402-2416. PubMed ID: 28632866
[TBL] [Abstract][Full Text] [Related]
16. Cancer screening with digital mammography for women at average risk for breast cancer, magnetic resonance imaging (MRI) for women at high risk: an evidence-based analysis.
Medical Advisory Secretariat
Ont Health Technol Assess Ser; 2010; 10(3):1-55. PubMed ID: 23074406
[TBL] [Abstract][Full Text] [Related]
17. Risk of Different Cancers Among First-degree Relatives of Pancreatic Cancer Patients: Influence of Probands' Susceptibility Gene Mutation Status.
Antwi SO; Fagan SE; Chaffee KG; Bamlet WR; Hu C; Polley EC; Hart SN; Shimelis H; Lilyquist J; Gnanaolivu RD; McWilliams RR; Oberg AL; Couch FJ; Petersen GM
J Natl Cancer Inst; 2019 Mar; 111(3):264-271. PubMed ID: 29982661
[TBL] [Abstract][Full Text] [Related]
18. Cancer Incidence in First- and Second-Degree Relatives of BRCA1 and BRCA2 Mutation Carriers.
Streff H; Profato J; Ye Y; Nebgen D; Peterson SK; Singletary C; Arun BK; Litton JK
Oncologist; 2016 Jul; 21(7):869-74. PubMed ID: 27306910
[TBL] [Abstract][Full Text] [Related]
19. The supplemental value of mammographic screening over breast MRI alone in BRCA2 mutation carriers.
Obdeijn IM; Mann RM; Loo CCE; Lobbes M; Voormolen EMC; van Deurzen CHM; de Bock G; ; Hooning MJ
Breast Cancer Res Treat; 2020 Jun; 181(3):581-588. PubMed ID: 32333294
[TBL] [Abstract][Full Text] [Related]
20. Relevance and efficacy of breast cancer screening in BRCA1 and BRCA2 mutation carriers above 60 years: a national cohort study.
Saadatmand S; Vos JR; Hooning MJ; Oosterwijk JC; Koppert LB; de Bock GH; Ausems MG; van Asperen CJ; Aalfs CM; Gómez Garcia EB; Meijers-Heijboer H; Hoogerbrugge N; Piek M; Seynaeve C; Verhoef C; Rookus M; Tilanus-Linthorst MM;
Int J Cancer; 2014 Dec; 135(12):2940-9. PubMed ID: 24789418
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
